XENON PHARMACEUTICALS INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
XENON PHARMACEUTICALS INC. (XENE) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $588.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-26
- XENON PHARMACEUTICALS INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $588.00K, a 272.15% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $158.00K.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $588.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | $158.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |